Sugi Predict

Sugi Predict / Compounds / SCHEMBL2322348

SCHEMBL2322348

SCHEMBL2322348

CC1CCCN(c2nnc(N)nc2-c2ccccc2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 8/20 1.00
▸ ADORA1 P30542 8/20 1.00
▸ LRRK2 Q5S007 1/20 0.50
▸ MAPT P10636 3/20 0.48
▸ TLR7 Q9NYK1 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ HRH2 P25021 1/20 0.44
▸ HRH3 Q9Y5N1 1/20 0.44
▸ PAK4 O96013 1/20 0.44
▸ FFAR2 O15552 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2320382 0.84 ADORA2A (0.73) ADORA2AADORA1LRRK2NPSR1HTT
SCHEMBL2324627 0.84 ADORA2A (0.72) ADORA2AADORA1HRH3
SCHEMBL2326196 0.82 ADORA2A (0.70) ADORA2AADORA1NPSR1HTTHRH2
SCHEMBL2323116 0.82 ADORA2A (0.70) ADORA2AADORA1NPSR1HTT
SCHEMBL2321443 0.82 ADORA2A (0.70) ADORA2AADORA1LRRK2NPSR1HTT
SCHEMBL2322355 0.82 ADORA2A (0.70) ADORA2AADORA1LRRK2ALDH1A1KDM4E
SCHEMBL2320238 0.82 ADORA2A (0.69) ADORA2AADORA1HTTALDH1A1KDM4E
SCHEMBL2323064 0.82 ADORA2A (0.69) ADORA2AADORA1NPSR1HTT
SCHEMBL2322947 0.82 ADORA2A (0.69) ADORA2AADORA1TLR7HTT
SCHEMBL2323881 0.81 ADORA2A (0.67) ADORA2AADORA1NPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988455-B2 1,2,4-triazine-4-amine derivatives HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-27 — — US claimed
US-20190047978-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2019-02-14 — — US claimed
US-20170291888-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2017-10-12 — — US claimed
US-20160175314-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2016-06-23 — — US claimed
US-9249130-B2 1,2,4-triazine-4-amine derivatives HEPTARES THERAPEUTICS LIMITED (GB) 2016-02-02 — — US claimed
US-20150005276-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2015-01-01 — — US claimed
US-20130029963-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2013-01-31 — — US claimed
CN-102822150-A 1,2, 4-triazin-4-amine derivatives HEPTARES THERAPEUTICS LTD 2012-12-12 — — CN claimed
US-12054472-B2 1,2,4-triazine-4-amine derivatives NXERA PHARMA UK LIMITED (GB) 2024-08-06 — — US disclosed
US-20230021177-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2023-01-19 — — US disclosed
US-10988455-B2 1,2,4-triazine-4-amine derivatives HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-27 — — US disclosed
US-20190047978-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2019-02-14 — — US disclosed
US-10112923-B2 1,2,4-triazine-4-amine derivatives HEPTARES THERAPEUTICS LIMITED (GB) 2018-10-30 — — US disclosed
US-20170291888-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2017-10-12 — — US disclosed
CN-102822150-B 1,2, 4-triazin-4-amine derivatives HEPTARES THERAPEUTICS LTD 2014-12-03 — — CN disclosed
US-8809525-B2 1,2,4-triazine-4-amine derivatives HEPTARES THERAPEUTICS LIMITED (GB) 2014-08-19 — — US disclosed
US-20130029963-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2013-01-31 — — US disclosed
EP-2531492-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES Heptares Therapeutics Limited (GB) 2012-12-12 — — EP disclosed
CN-102822150-A 1,2, 4-triazin-4-amine derivatives HEPTARES THERAPEUTICS LTD 2012-12-12 — — CN disclosed
WO-2011095625-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2011-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005276-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885LRRK2 3729/4885
US-20190047978-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885LRRK2 3729/4885
US-10988455-B2 1,2,4-triazine-4-amine derivatives ADORA2B, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885LRRK2 3729/4885
US-20160175314-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885LRRK2 3659/4885
US-20230021177-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885LRRK2 3537/4885
US-10112923-B2 1,2,4-triazine-4-amine derivatives ADORA2B, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885LRRK2 3643/4885
US-12054472-B2 1,2,4-triazine-4-amine derivatives ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885LRRK2 1200/4885
US-20170291888-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES PTGER1, LTB4R2, LTB4R ADORA2A 29/4885ADORA1 19/4885LRRK2 4084/4885
US-20130029963-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885LRRK2 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.